Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta‐analysis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: Case–control studies have not been consistent in showing association between apolipoprotein E (APOE) polymorphisms and frontotemporal lobar degeneration (FTLD), producing contradictory findings. The study objective was to define and quantify further the disease risk associated with the carriage of different APOE alleles to determine whether APOE gene polymorphism is a risk factor for FTLD. Methods: A systematic review of all case–control studies investigating the association between the APOE gene and FTLD up to December 2011 was conducted. Case–control studies using clinical or pathological criteria for FTLD and reporting APOE allelic or genotypic data were included. Pooled odds ratios (ORs) were estimated using a random effects model, and 95% confidence intervals (CIs) were calculated. Results: Twenty‐eight case–control studies met the inclusion criteria. Carriage of the ε2 allele had no effect on disease risk. On the contrary, carriage of the ε4 allele was associated with a significantly increased disease risk (ε4 carriers vs non‐ε4 carriers: OR, 1.94; 95% CI, 1.43–2.64; ε4 vs ε3 allele: OR, 1.83; 95% CI, 1.34–2.52). Furthermore, a gene–dosage effect for the ε4 allele was found. There was no evidence of publication bias, but heterogeneity between the studies was high. Conclusions: Our study provides evidence for an association between the APOE ε4 allele and frontotemporal lobar degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Rubino, E., Rainero, I., Chiò, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e25df · Cited by 286
Self-citationIn vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187 · cited 1×
“In patients with FTLD, neuroimaging and genetic studies suggested that an enhanced inflammatory response might be involved in disease risk and progression [46,47].”
Agosta, F., Vossel, K. A., Miller, B. L., Migliaccio, R., Bonasera, S. J., Filippi, M., Boxer, A. L., Karydas, A., Possin, K. L., & Gorno-Tempini, M. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812697106 · Cited by 178
Cited by
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
“The genetic advances in frontotemporal lobar degeneration (FTLD) and ALS over the last decade have been astounding (DeJesus-Hernandez et al., 2011; Renton et al., 2011).”
InfluentialAPOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies
Goldberg, T. E., Huey, E. D., & Devanand, D. P. (2020) · Nature Communications · doi:10.1038/s41467-020-18198-x · Cited by 82
APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases
Shvetcov, A., Johnson, E. C. B., Winchester, L. M., Walker, K. A., Wilkins, H. M., Thompson, T. G., Rothstein, J. D., Krish, V., Imam, F. B., The Global Neurodegeneration Proteomics Consortium (GNPC), et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03835-z · Cited by 78
APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
Meneses, A. D., Koga, S., Li, Z., O'Leary, J., Li, F., Chen, K., Murakami, A., Qiao, W., Kurti, A., Heckman, M. G., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26580 · Cited by 11
Metadata
- Authors
- Rubino, E., Vacca, A., Govone, F., De Martino, P., Pinessi, L., & Rainero, I.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-05-20
- Volume
- 9
- Issue
- 6
- Pages
- 706-713
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2075467558
- Cited by
- 43
- References
- 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta‐analysis. https://app.cochat.ai/papers/10.1016/j.jalz.2012.10.013
- The paper
- Rubino, E., Vacca, A., Govone, F., De Martino, P., Pinessi, L., & Rainero, I. (2013). Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta‐analysis. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.10.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.